Tag Archives: cardiovascular disease

The following expert faculty members have received an honorarium for participating at the meeting Faculty member Affiliation Professor Amitava Banerjee Professor of Clinical Data Science, Institute of Health Informatics, University College London; Consultant Cardiologist, University College London Hospitals and Barts Health NHS Trust Professor Sir Mark Caulfield Professor of Clinical Pharmacology, Queen Mary University of London & Vice-Principal for Health for Queen Mary’s Faculty of Medicine and Dentistry Professor Keith Fox Professor of Cardiology, University of Edinburgh & British Heart Foundation Professor of Cardio

Faculty Faculty member Affiliation Professor Ahmet Fuat PCCS Council Member and GPSI Cardiology, County Durham Professor Chris Gale Professor of Cardiovascular Medicine and Honorary Consultant Cardiologist, University of Leeds Dr Guy Lloyd Consultant Cardiologist, Barts Heart Centre and Honorary Secretary, BCS Helen Williams National Specialty Adviser for CVD Prevention, NHSE & NHSI and Consultant Pharmacist for CVD, SE London CCG and UCL Partners Dr Jim Moore President of the PCCS and GPSI Cardiology, Gloucestershire Trudie Lobban, MBE Founder of the AF Association Professor Vijay Kunadian Professor of Interventional

There is substantial evidence that a diet rich in fish results in lower levels of atherosclerosis. This has led to the hypothesis that fish oils, which are known to reduce triglyceride levels – an independent risk for cardiovascular events – might also reduce the level of cardiovascular disease possibly by lowering triglycerides. The open-label Japan EPA Lipid Intervention Study (JELIS) used a highly purified, fish oil extract containing only eicospentaenoic acid (EPA) and showed a reduction in cardiovascular events.3 This led to the large, randomised, double-blind, placebo-controlled, multinational trial called the Reduction of Cardiovas

Vaduganathan et al. aggregated results from five heart failure trials,3 and the Nuffield Department of Population Health Renal Studies Group with the SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium combined standardised data from 13 large placebo-controlled SGLT2 inhibitor trials from three different patient populations. It included results from trials studying 42,568 patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, 21,974 patients in heart failure trials, and 25,898 patients in CKD trials.4 Across the 13 trials, the risk of the composite of hospitalisation for heart failure or cardiovas

Introduction Dr Cong Ying Hey Disparities in cardiovascular (CV) morbidity and mortality are among the major health and social care concerns in our modern society. In the UK, people living in the most deprived areas are four times more likely to die prematurely from CV disease (CVD) than those living in the least deprived areas.1 To address the disparities in CV outcomes, it is imperative to recognise the presence of inequalities at different interfaces of cardiology services. This article, therefore, aims to provide a focused discussion concerning potential measures to reduce health inequalities in cardiology through the lens of the challeng

Introduction to the steering committee From left to right: Professor Martin Cowie, Dr Matthew Fay, Ms Jo Jerrome,Dr Abhishek Joshi, Dr Jim Moore, Ms Helen Williams Conflicts of interest The steering committe received speaking and consultation fees from Bayer plc. MRC provides consultancy advice to Abbott, AstraZeneca, Bayer, Boston Scientific, Medtronic, Novartis, Roche Diagnostics and Servier. MF has received speaker honoraria, conference sponsorship, unrestricted educational grants, and/or attended meetings sponsored by AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Medtronic, Novartis, Pfizer, Roche, Sanofi-Aventis, and S

End-stage renal disease (ESRD) represents a state of dysregulation of many processes including inflammation, endothelial dysfunction, vascular calcification, bone mineral metabolism, oxidative stress, autonomic balance, uraemia, volume control, coagulation, insulin resistance, and haematopoiesis. The process of haemodialysis, the most common form of renal replacement therapy, causes myocardial stunning, leading to strain and potential damage,2 and can create a pro-arrhythmic environment.3 The early dialysis period is indeed high risk, with more cardiovascular events reported within the first five months of dialysis.4 It is, therefore, not an

Leading experts treating COVID-19 patients now provide advice on managing cardiovascular disease during the pandemic. New European Society of Cardiology (ESC) guidance provides healthcare professionals with the best available knowledge, based on practical experience, on how to diagnose and manage cardiovascular conditions in COVID-19 patients, treat the coronavirus infection, and organise and prioritise care. It will be updated as more evidence is gathered. The authors stress that document is not a guideline but rather a guidance document. The recommendations are the result of observations and personal experience from health care providers at

Introduction The ASPirin in Reducing Events in the Elderly trial (ASPREE), published in 2018, was a landmark randomised-controlled trial (RCT) that contributed important knowledge about primary cardiovascular disease (CVD) prevention among healthy older adults.1 ASPREE found that daily low-dose aspirin (LDA) does not statistically prevent disability or CVD among adults aged over 70 years when compared with placebo, but does significantly increase risk of haemorrhage; findings that immediately influenced clinical practice guidelines.2 When used as a case study of large RCTs, ASPREE provides further, more existential, lessons for both researche

Introduction Cholesterol is a key risk factor for atheroma and coronary heart disease. The evidence-base for high-intensity lipid-lowering therapy in secondary prevention of cardiovascular disease is unequivocal.1-4 Despite the introduction of novel drugs, including ezetimibe5,6 and monoclonal antibodies,7 statins remain first-line therapy.8,9 Statins decrease hepatic cholesterol synthesis by competitively inhibiting 5-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase receptors, as they have an affinity up to 10,000 times greater than the natural substrate.10 Through reducing intra-cellular cholesterol concentration, statins up-regulate